Cor Vasa 2008, 50(3):133-138 | DOI: 10.33678/cor.2008.045

Heart transplantation

Lenka Špinarová
I. interní kardioangiologická klinika, Fakultní nemocnice u sv. Anny a Lékařská fakulta Masarykovy univerzity, Brno, Česká republika

Over the past two decades, orthotopic heart transplantation (OHTx) has become the established method for the treatment of severe heart failure. Challenges faced in the post-transplant period include immunosuppressive therapy and drug interactions, side effects of immunosuppression, rejection, and infection. Main immunosuppressives include calcineurin inhibitors, corticosteroids, antiproliferative agents and, as a separate class, drugs for induction therapy. Side effects of immunosuppression include hyperlipidemia, hypertension, nephropathy, diabetes mellitus, liver dysfunction, osteoporosis, impaired hematopoiesis, and an increased incidence of malignancies. Rejection may be peracute, acute, or chronic as graft vasculopathy. Infection may have a varied etiology, commonly being opportune, viral, and fungal. The side effects of immunosuppressive therapy are always outweighed by dramatic improvement in the quality of life of the patient and their family members and other people often in contact with the patient.

Keywords: Heart transplantation; Immunosuppression; Rejection; Quality of life

Published: March 1, 2008  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Špinarová L. Heart transplantation. Cor Vasa. 2008;50(3):133-138. doi: 10.33678/cor.2008.045.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Martínek V, Matoušovic K, Špatenka J. Objev a užití cyklosporinu v klinické praxi. Prakt Lék 2002;82:14-20.
    2. Hošková L, Málek I, Šedivý J, a spol. Lékové interakce cyklosporinu A. Cor Vasa 2002;44:481-8.
    3. Rinaldi M, Pellegrini C, Martinelli L, et al. FK 506 effectiveness in reducing rejection after heart transplantation: a prospective randomised study. J Heart Lung Transpl 1997;16:1001-10.
    4. Špinarová L, Toman J, Hude P, et al. Dlouhodobé metabolické účinky tacrolimu a cyklosporinu po transplantaci srdce. Sborník abstrakt V. konference transplantace orgánů a tkání, Brno 2002:41
    5. Gebauerová M, Jandová R, Málek I, a spol. Obraz nemocného po srdeční transplantaci. Cor Vasa 1993;35: 258-62.
    6. Špinarová L, Hude P, Krejčí J a spol. Vývoj imunosupresivních režimů v průběhu 10 let u pacientů po transplantaci srdce. Sborník abstrakt 6. kongresu České transplantační společnosti, str. 15, Praha 14.-16. 10. 2004.
    7. Špinarová L, Toman J. Pharmacotherapy after heart transplantation. Cor Vasa 2000;42:335-40.
    8. Snell GI, Levvey BJ, Chin W, et al. Sirolimus allows renal recovery in lung and heart transplant recipients with chronic renal impairment. J Heart Lung Transpl 2002;21:540-6. Go to original source... Go to PubMed...
    9. Hunt J, Lerman M, Dewey T, et al. Conversion to sirolimus lessens renal dysfunction in heart transplant patients. J Heart Lung Transpl 2004;23(2S):113. Go to original source...
    10. Viklický O, Matl I. Rapamycin: nové imunosupresivum schopné potlačit chronickou rejekci? Čas Lék čes 2001; 140:22-5.
    11. Mancini D, Pinney S, Burkhoff D, et al. Use of rapamycin slows progression of cardiac transplantation vasculopathy. Circ 2003;108:48-53. Go to original source... Go to PubMed...
    12. Groetzner J, Kaczmarek I, Muller M, et al. Calcineurin inhibitor-free immunosuppression with mycophenolatmofetil and sirolimus after cardiac transplantation is safe and improves renal function significantly: 1 year follow up. Am Transpl Congress, Boston, USA, May 2004. Go to original source...
    13. Rothenburger M, Zuckermann A, Bara C, et al. Recommendations for the use of everolimus (Certican) in heart transplantation: results from the second German-Austrian Certican Conferrence. J Heart and Lung Transpl 2007;26:305-11. Go to original source... Go to PubMed...
    14. Vítovec J, Špinar J. Farmakoterapie kardiovaskulárních onemocnění. Praha: Grada, 2004:248.
    15. Keogh A, Mecdonald P, Kaan A, et al. Efficacy and Safety of Pravastatin vs Simvastatin After Cardiac Transplantation. J Heart Lung Transplant 2000;19:529-37. Go to original source... Go to PubMed...
    16. Kobashigawa JA, Moriguchi JD, Cogert G, et al. 10-year results of the pravastatin randomized trial in heart transplant recipients. ISHLT, April 21-24, 2004, San Francisco, USA. Abstract 218. Go to original source...
    17. Špinarová L, Toman J. Fluvastatin u pacientů po transplantaci srdce. Vnitř lék 1998;44:13-6. Go to PubMed...
    18. Hošková L, Podzimková M, Málek I. Bezpečnost a účinnost fluvastatinu po transplantaci srdce. Cor Vasa 2004; 46:473-7.
    19. Špinarová L. Hypertenze po transplantaci srdce. Vnitř Lék 1999;45:555-8. Go to PubMed...
    20. Ventura HO, Mehra MR, Stapleton DD, et al. Cyclosporine induced hypertension in cardiac transplantation. Med Clin North America 1997;81:1347-57. Go to original source... Go to PubMed...
    21. Schroeder JS, Gao SZ, Aldermann EL, et al. A preliminary study of diltiazem in the prevention of coronary artery disease in heart-transplant recipients. New Engl J Med 1993;328:164-70. Go to original source... Go to PubMed...
    22. Brozena SC, Johnson MR, Ventura HO, et al. Effectiveness and safety of diltiazem or lisinopril in treatment of hypertension after heart transplantation. J Am Coll Cardiol 1996;27:1707-12. Go to original source...
    23. Midivedt K, Neumayer HH. Management strategies for posttransplant hypertension. Transplantation 2000;70: SS64-9. Go to PubMed...
    24. Wagoner LE. Management of the cardiac transplant recipient: roles of the transplant cardiologist and primary care physician. Am J Med Sci 1997;314:173-84. Go to original source...
    25. Krejčí J, Hude P, Špinarová L, et al. Transplantace srdce - indikace, komplikace, terapie - naše zkušenosti ze sledování 100 pacientů po srdeční transplantaci. Vnitř Lék 2000;46:750-5. Go to PubMed...
    26. Rich GM, Mudge GH, Laffel GL, et al. Cyclosporine A and prednison-associated osteoporosis in heart transplant recipients. J Heart Lung Transpl 1992;11:950-8.
    27. Penn I. Cancer following cyclosporine therapy. Transplantation 1987;43:32-5. Go to original source... Go to PubMed...
    28. Sullivan JI, Medveczky P, Forman SJ. Ebstein-Barr virus induced lymfoproliferation: Implications for antiviral chemotherapy. New Engl J Med 1994;311:1163-7. Go to original source... Go to PubMed...
    29. Billingham ME, Cary NR, Hammond ME, et al. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection. Heart rejection Study Group. The International Society for Heart and Lung Transplantation. J Heart Transplant 1990;9:587-93.
    30. Málek I. Transplantace srdce. Postgraduální medicína 1999;1:95-100.
    31. Gao SZ, Alderman EL, Schroeder JS, et al. Accelerated coronary vascular disease in the heart transplant patient: Coronary artery findings. J Am Coll Cardiol 1988;12: 34-40. Go to original source... Go to PubMed...
    32. Grattan MT, Moreno-Cabral CE, Starnes VA, et al. Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. JAMA 1989;261: 3561-6. Go to original source...
    33. Špinarová L. Transplantace srdce z pohledu kardiologa. Kardiologická revue 1999;2:101-5.

    Return to the content


    Cor et Vasa

    You are accessing a site intended for medical professionals, not the lay public. The site may also contain information that is intended only for persons authorized to prescribe and dispense medicinal products for human use.

    I therefore confirm that I am a healthcare professional under Act 40/1995 Coll. as amended by later regulations and that I have read the definition of a healthcare professional.


    No
    Yes